About Regeneron Pharmaceuticals, Inc. Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA ® (aflibercept) Injection, ZALTRAP ® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST ® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Regeneron has filed a regulatory application with the U.S. Food and Drug Administration (FDA) for a second indication for EYLEA. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia. Additional information and recent news releases are available on the Regeneron web site at www.regeneron.com.Contact Information: Peter Dworkin Corporate Communications 914.847.7640 email@example.com Manisha Narasimhan, Ph.D. Investor Relations 914.847.5126 firstname.lastname@example.org SOURCE Regeneron Pharmaceuticals, Inc.